Enlivex Therapeutics Ltd.
ENLV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.05 | -0.01 | 0.16 |
| FCF Yield | -54.63% | -47.37% | -44.26% | -17.17% |
| EV / EBITDA | -1.47 | -1.78 | -1.18 | -5.39 |
| Quality | ||||
| ROIC | -63.78% | -94.47% | -41.82% | -21.19% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.81 | 0.77 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | 44.82% | 25.93% | -67.34% | -59.38% |
| Safety | ||||
| Net Debt / EBITDA | 0.19 | -0.01 | 1.72 | 0.56 |
| Interest Coverage | -1,195.08 | -2,099.64 | -4.90 | -58.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.66 | -0.04 |
| Cash Conversion Cycle | -543.15 | -361.50 | -362.18 | -8,744.62 |